Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1995-06-07
2001-08-21
Ulm, John (Department: 1812)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S173300, C435S252300, C435S320100, C530S350000, C536S023500
Reexamination Certificate
active
06277591
ABSTRACT:
BACKGROUND OF THE INVENTION
This invention relates to dopamine receptors from mammalian species and the corresponding genes. In particular, it relates to the isolation, sequencing and/or cloning of D
2
dopamine receptor genes, the synthesis of D
2
dopamine receptors by transformed cells, and the manufacture and use of a variety of novel products enabled by the identification and cloning of DNA encoding dopamine receptors.
Dopamine receptors in general have been implicated in a large number of neurological and other disorders, including, for example, movement disorders, schizophrenia, drug addiction, Parkinson's disease, Tourette syndrome, Tardive Dyskinesia, and many others. As a result, the dopamine receptor has been the subject of numerous pharmacological and biochemical studies.
In general, dopamine receptors can be classified into D
1
and D
2
subtypes based on pharmacological and biochemical characteristics (1,2). The D
2
dopamine receptor has been implicated in the pathophysiology and treatment of the mentioned disorders. In addition, it is known that the D
2
dopamine receptor interacts with guanine nucleotide binding proteins to modulate second messenger systems (6,7).
Despite the heavy emphasis placed on elucidation of the existence and properties of the dopamine receptor and its gene, identification, isolation and cloning have been inaccessible heretofore. This is true despite the knowledge that other members of the family of receptors that are coupled to G proteins share a significant similarity in primary amino acid sequence and exhibit an archetypical topology predicted to consist of seven putative transmembrane domains (8). Regarding the serotonin receptor, e.g., see Julius et al., Science, Vol. 241, 558 (1988).
SUMMARY OF THE INVENTION
This invention has successfully identified, isolated and cloned mammalian, including human, D
2
dopamine receptor gene sequences and produced the encoded dopamine receptor. The corresponding polypeptide has been synthesized. Sequences of both the gene and the polypeptide have been determined. The invention also provides a variety of new and useful nucleic acid, cell line, vector, and polypeptide and medicinal products, inter alia, as well as methods of using these.
Thus, this invention relates to an isolated DNA sequence, an identified portion of which is a structural gene which encodes a polypeptide having the biological activity of a mammalian D
2
dopamine receptor. In particular, it relates to an isolated DNA sequence which will hybridize to a DNA sequence encoding a mammalian D
2
dopamine receptor. It also relates to fragments, variants and mutants of such sequences, particularly those which also encode a polypeptide having biological activity of a mammalian dopamine receptor, most particularly a mammalian D
2
dopamine receptor. In a preferred aspect, the dopamine receptor is human. In another preferred aspect, the sequence is that of rat D
2
dopamine receptor as shown in FIG.
1
. Of course, the nucleic acids of this invention also include complementary strands of the foregoing, as well as sequences differing therefrom by codon degeneracy and sequences which hybridize with the aforementioned sequences.
In other preferred aspects, this invention includes nucleic acid sequences and fragments useful as oligonucleotide probes, preferably labelled with a detectable moiety such as a radioactive or biotin label. For example, such probes can hybridize with DNA encoding a polypeptide having the biological activity of a D
2
dopamine receptor or with DNA associated therewith, e.g., DNA providing control of a D
2
dopamine receptor gene or introns thereof, etc. DNA of this invention can also be part of a vector.
The invention also involves cells transformed with vectors of this invention as well as methods of culturing these cells to manufacture polypeptides, e.g., having the biological activity of a D
2
dopamine receptor. Preferably, the cells are of mammalian origin when used in such methods.
The invention also relates to polypeptides encoded by the foregoing nucleic acid sequences, especially to isolated mammalian dopamine receptors, preferably of human origin. The invention further relates to polypeptides which are mutants or variants of such receptors, preferably those wherein one or more amino acids are substituted for, inserted into and/or deleted from the receptor, especially those mutants which retain the biological activity of a dopamine receptor. This invention also relates to antibodies, preferably labelled, and most preferably monoclonal, capable of binding a dopamine receptor amino acid sequence, preferably wherein the latter is human, or a fragment of such an antibody.
The invention further relates to compositions comprising one of the various products mentioned above and, typically, a pharmaceutically acceptable carrier as well as to methods of employing these products to achieve a wide variety of utilitarian results.
REFERENCES:
patent: 4675285 (1987-06-01), Clark et al.
patent: 4705858 (1987-11-01), Hadley
patent: 4736866 (1988-04-01), Leder et al.
Casey et al., Nucleic Acids Research, vol. 4, No. 5, pp. 1539-1552 (Dec. 24, 1976).
Dixon et al., Nature 321:75-79 (May 1, 1986).
Krust et al., EMBO J., 5:891-897 (May 1986).
Kubo et al., Nature, 323:411-416 (Oct. 2, 1986).
Kobilka et al., J.B.C., 262(15), pp. 7321-7327 (May 25, 1987).
Kobilka et al., Nature, 329:75-79 (Sep. 3, 1987).
Britten et al., Meth. in Enzymology, vol. 19, Part E, pp.363-418, “Analysis of Repeating DNA Sequences by Reassociation”.
Grigoriadis et al., FEBs Let. 227:220-224 (Jan. 1988).
Sims et al., Science 241:585-589 (Jul. 29, 1988).
Hauptmann et al.Nucleic Acids Research13(13): 4734-4749, 1985.
Bunzow James R.
Civelli Olivier
Grandy David K.
Machida Curtis A.
McDonnell & Boehnen Hulbert & Berghoff
Oregon Health & Science University
Ulm John
LandOfFree
Dopamine receptors and genes does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dopamine receptors and genes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dopamine receptors and genes will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2472929